Universität zu Köln

Rippinger, Nathalie, Fischer, Christine, Sinn, Hans-Peter ORCID: 0000-0003-2836-6699, Dikow, Nicola, Sutter, Christian, Rhiem, Kerstin, Grill, Sabine, Cremer, Friedrich W., Nguyen, Huu P., Ditsch, Nina, Kast, Karin, Hettmer, Simone, Kratz, Christian P. and Schott, Sarah (2021). Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study. Cancer Med., 10 (21). S. 7747 - 7759. HOBOKEN: WILEY. ISSN 2045-7634

Full text not available from this repository.

Abstract

Background Women with Li-Fraumeni syndrome (LFS) have elevated breast cancer (BC) risk. Optimal BC treatment strategies in this population are yet unknown. Methods BC subtypes and treatment were retrospectively investigated between December 2016 and January 2019 in a multicentre study. BC risks were evaluated according to the type of surgery. Results Thirty-five women of our study population (35/44; 79.5%) had developed 36 breast lesions at first diagnosis at a mean age of 34 years. Those breast lesions comprised 32 invasive BCs (89%), three ductal carcinoma in situ alone (8%) and one malignant phyllodes tumour (3%). BCs were mainly high-grade (18/32), of no special type (NST; 31/32), HER2-enriched (11/32) or luminal-B-(like)-type (10/32). Affected women (n = 35) received breast-conserving surgery (BCS, n = 17) or a mastectomy (ME, n = 18) including seven women with simultaneous contralateral prophylactic mastectomy (CPM) at first diagnosis. Nineteen women suffered 20 breast or locoregional axillary lesions at second diagnosis with mean age of 36. Median time between first and second diagnosis was 57 months; median time to contra- and ipsilateral recurrence depended on surgical strategies (BCS: 46 vs. unilateral ME: 93 vs. bilateral ME > 140 months). Women with a primary treatment of solitaire therapeutic ME suffered from contralateral BC earlier compared to those with therapeutic ME and CPM (median: 93 vs. >140 months). Conclusion Aggressive BC subtypes occur among women with LFS. Surgical treatment, i.e. ME and CPM, may prolong time to a second BC diagnosis. Conclusion on long-term survival benefit is pending. Individual competing tumour risks and long-term outcomes need to be taken into consideration.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Rippinger, Nathalie UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Christine UNSPECIFIED UNSPECIFIED UNSPECIFIED Sinn, Hans-Peter UNSPECIFIED orcid.org/0000-0003-2836-6699 UNSPECIFIED Dikow, Nicola UNSPECIFIED UNSPECIFIED UNSPECIFIED Sutter, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Rhiem, Kerstin UNSPECIFIED UNSPECIFIED UNSPECIFIED Grill, Sabine UNSPECIFIED UNSPECIFIED UNSPECIFIED Cremer, Friedrich W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Nguyen, Huu P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ditsch, Nina UNSPECIFIED UNSPECIFIED UNSPECIFIED Kast, Karin UNSPECIFIED UNSPECIFIED UNSPECIFIED Hettmer, Simone UNSPECIFIED UNSPECIFIED UNSPECIFIED Kratz, Christian P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schott, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-601840
DOI:	10.1002/cam4.4300
Journal or Publication Title:	Cancer Med.
Volume:	10
Number:	21
Page Range:	S. 7747 - 7759
Date:	2021
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	2045-7634
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CONTRALATERAL PROPHYLACTIC MASTECTOMY; TP53 MUTATION CARRIERS; QUALITY-OF-LIFE; SATISFACTION; PREDICTORS; SARCOMAS; PATIENT; BRCA1 Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/60184